Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, His Tag (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
CD6-C52H5-100ug
$270.00
CD6-C52H5-1mg (500ug X 2)
$1700.00
ETA of in-stock products:2 business days

Product Details

  • Synonym

    CD86, B7-2, B70, CD28LG2, LAB72, MGC34413

  • Source

    Cynomolgus / Rhesus macaque B7-2, His Tag (MALS verified) (CD6-C52H5) is expressed from human 293 cells (HEK293). It contains AA Ala 19 - His 240 (Accession # G7NXR4-1). In the region Ala 19 - His 240, the AA sequence of Cynomolgus and Rhesus macaque B7-2 are homologus.

    Predicted N-terminus: Ala 19

    Request for sequence

  • Molecular Characterization

    B7-2 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 27.3 kDa. The protein migrates as 40-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    B7-2 SDS-PAGE

    Cynomolgus / Rhesus macaque B7-2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    B7-2 SEC-MALS

    The purity of Cynomolgus / Rhesus macaque B7-2, His Tag (Cat. No. CD6-C52H5) is more than 95% and the molecular weight of this protein is around 35-58 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     B7-2 ELISA

    Immobilized Cynomolgus / Rhesus macaque CTLA-4, Fc Tag (Cat. No. CT4-C5256) at 5 μg/mL (100 μL/well) can bind Cynomolgus / Rhesus macaque B7-2, His Tag (HPLC-verified) (Cat. No. CD6-C52H5) with a linear range of 0.312-5 μg/mL (QC tested).

    Protocol
  •  B7-2 ELISA

    Immobilized Cynomolgus / Rhesus macaque B7-2, His Tag (HPLC-verified) (Cat. No. CD6-C52H5) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) with a linear range of 0.02-0.625 μg/mL (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

Recent Advances

 
Drug Development Progress
  • English Name:

    Cluster of differentiation 86

  • Category:

  • Approved Drugs:

    2 Details

  • Drugs in Clinical Trials:

    7 Details

  • Highest Development Stage:

    Approved

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background